Certified by Founder Lodge
Advent Life Sciences
United Kingdom - London
INVESTOR
1 Disclosed Funding Rounds $40,000,000
14 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Advent Life Sciences is one of the leading trans-Atlantic venture investors focused on building innovative Life Sciences businesses in the UK, Europe and the USA. We are a highly experienced
| Company | Date | Round | Raised |
|---|---|---|---|
 Artax Biopharma Inc |
August, 07 ,2024 | Unknown | $8,000,000 |
 Beacon Therapeutics |
July, 10 ,2024 | Series B | $170,000,000 |
 F2G |
September, 13 ,2024 | Unknown | $100,000,000 |
 Moximed |
August, 16 ,2022 | Series C | $40,000,000 |
 Proximie |
August, 14 ,2022 | Series C | $80,000,000 |
 Relief Cardiovascular |
January, 09 ,2025 | Series A | $12,000,000 |
 Nalu Medical, Inc. |
January, 05 ,2024 | Unknown | $65,000,000 |
 Glycomine Inc. |
April, 17 ,2025 | Series C | $115,000,000 |
 Curve Therapeutics |
February, 28 ,2024 | Series A | $51,183,495 |
| Beacon Therapeutics |
July, 10 ,2024 | Series B | $170,000,000 |
| Artax Biopharma Inc |
August, 07 ,2024 | Unknown | $8,000,000 |
| F2G |
September, 13 ,2024 | Unknown | $100,000,000 |
| Relief Cardiovascular |
January, 09 ,2025 | Series A | $12,000,000 |
| Glycomine Inc. |
April, 17 ,2025 | Series C | $115,000,000 |
Cherry Ventures
Blue Bear Capital
Slow Ventures
Climate Capital
Eniac Ventures
Helex | $3,500,000 | (Nov 4, 2025)
xMEMS | $21,000,000 | (Nov 4, 2025)
catalyx space | $5,400,000 | (Nov 4, 2025)
Cephia AI | $4,000,000 | (Nov 4, 2025)
Ornn | $5,700,000 | (Nov 4, 2025)
